Ptc Therapeutics (PTCT) Depreciation & Amortization (CF) (2020 - 2026)

Ptc Therapeutics' Depreciation & Amortization (CF) history runs 15 years deep, the most recent figure standing at $15.9 million for Q2 2026.

• In Q2 2026, Depreciation & Amortization (CF) rose 109.34% year-over-year to $15.9 million; the TTM figure through Jun 2026 stood at $55.3 million (up 97.11% YoY), while the FY2025 annual figure was $38.8 million, down 48.7% from the prior year.
• Depreciation & Amortization (CF) for Q2 2026 stood at $15.9 million, up from $15.4 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $80.7 million in Q4 2023, with the low at $6.5 million in Q3 2024.
• The 5-year median for Depreciation & Amortization (CF) is $21.1 million (2022), against an average of $28.4 million.
• The sharpest annual moves came in 2024 and 2026: Depreciation & Amortization (CF) slumped 91.62% in 2024, then surged 113.45% in 2026.
• Ptc Therapeutics' Depreciation & Amortization (CF) stood at $38.9 million in 2022, then soared by 107.65% to $80.7 million in 2023, then plunged by 91.62% to $6.8 million in 2024, then soared by 90.75% to $12.9 million in 2025, then gained by 23.04% to $15.9 million in 2026.
• Business Quant data shows PTCT's Depreciation & Amortization (CF) at $15.9 million in Q2 2026, $15.4 million in Q1 2026, and $12.9 million in Q4 2025.